The pivotal role of systemic IL-17 and IL-23 levels in psoriasis has been validated clinically with neutralizing antibodies (e.g. Ixekizumab, Secukinumab, Guselkumab and Tildrakizumab). Here, IL17A is linked to psoriasis.